Loading
PDBj
MenuPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

9DQF

Crystal structure of bifunctional GlmU from Staphylococcus aureus NCTC 8325 complexed with acetyl CoA and citrate

Summary for 9DQF
Entry DOI10.2210/pdb9dqf/pdb
DescriptorBifunctional protein GlmU, ACETYL COENZYME *A, CITRIC ACID, ... (4 entities in total)
Functional Keywordsuridyltransferase, acetyltransferase, transferase
Biological sourceStaphylococcus aureus subsp. aureus NCTC 8325
Total number of polymer chains1
Total formula weight50724.47
Authors
Pederick, J.L.,Bruning, J.B. (deposition date: 2024-09-24, release date: 2025-05-14)
Primary citationPederick, J.L.,Kumar, A.,Pukala, T.L.,Bruning, J.B.
Functional and structural characterization of Staphylococcus aureus N-acetylglucosamine 1-phosphate uridyltransferase (GlmU) reveals a redox-sensitive acetyltransferase activity.
Protein Sci., 34:e70111-e70111, 2025
Cited by
PubMed Abstract: The bifunctional enzyme N-acetylglucosamine 1-phosphate uridyltransferase (GlmU) is a promising antibiotic drug target, as it facilitates the biosynthesis of uridine 5'-diphospho-N-acetylglucosamine, an essential precursor of cell wall constituents. We identified that Staphylococcus aureus GlmU (SaGlmU), which was previously targeted for inhibitor development, possesses a dual-cysteine variation (C379/C404) within the acetyltransferase active site. Enzyme assays performed under reducing and non-reducing conditions revealed that the acetyltransferase activity of SaGlmU is redox-sensitive, displaying ~15-fold lower turnover and ~3-fold higher K value for the acetyl CoA substrate under non-reducing conditions. This sensitivity was absent in a C379A SaGlmU mutant. Analysis of SaGlmU by mass spectrometry, x-ray crystallography, and in silico modeling support that C379 and C404 act as a reversible, redox-sensitive switch by forming a disulfide under non-reducing conditions that impedes acetyl CoA recognition and turnover. Therefore, we recommend that future in vitro screening and characterization of SaGlmU inhibitors consider both reducing and non-reducing conditions.
PubMed: 40143772
DOI: 10.1002/pro.70111
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (1.9 Å)
Structure validation

246704

PDB entries from 2025-12-24

PDB statisticsPDBj update infoContact PDBjnumon